

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Akesobio

Akeso, Inc.

康方生物科技（開曼）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT

AK112-303/HARMONI-2 WAS ACCEPTED AS LBA OF 2024 WCLC PRESIDENTIAL SYMPOSIUM ORAL PRESENTATION

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the results of AK112-303/HARMONI-2, the Phase III clinical trial of 依達方[®] (ivonescimab, PD-1/VEGF), a novel global first-in-class PD-1/VEGF bi-specific immuno-therapy drug independently developed by the Company, monotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer (“**NSCLC**”) patients with positive PD-L1 expression (PD-L1 TPS \geq 1%) have been successfully accepted as the Late-Breaking Abstract (LBA) of IASLC 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC). Dr. ZHOU Caicun, the principal investigator (PI) of this trial, will give an oral presentation on the full data at the conference’s Presidential Symposium.

Ivonescimab is the world’s first and only drug to show superior efficacy compared with pembrolizumab as monotherapy in a Phase III head-to-head setting. Recently, the Company has submitted the supplemental New Drug Application (sNDA) of this indication to the National Medical Products Administration (“**NMPA**”) of China.

ABOUT AK112-303/HARMONI-2

AK112-303/HARMONI-2 (CTR20222137) is a randomized, double-blind, registrational Phase III clinical trial to evaluate ivonescimab (依達方[®]) versus pembrolizumab as first-line monotherapy for locally advanced or metastatic NSCLC patients with positive PD-L1 expression (PD-L1 TPS \geq 1%) with primary endpoint of PFS. 398 participants were enrolled in this trial, and approximate 57.8% of participants were with PD-L1 TPS 1-49% and 42.2% of participants with PD-L1 TPS \geq 50%, which is in line with real world scenario.

ABOUT 依達方[®] (IVONESCIMAB, PD-1/VEGF)

依達方[®] (ivonescimab) is a novel global first-in-class PD-1/VEGF bi-specific immunotherapy drug independently developed by the Company. On May 24, 2024, 依達方[®] was granted marketing approval by NMPA for the treatment of EGFR mutated locally advanced or metastatic non-squamous NSCLC patients who have progressed after EGFR TKI treatment. Currently, ivonescimab's first indication has been approved in China, and the Company is conducting 5 Phase III trials including 2 global MRCTs and 4 registrational trials versus PD-1. The Company is also conducting multiple clinical trials of ivonescimab covering 16 indications including gastrointestinal cancer, hepatocellular carcinoma and colorectal cancer.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairwoman and executive Director

Hong Kong, August 12, 2024

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.